

DRUG PRIOR AUTHORIZATION COMMITTEE

March 15, 2018

AGENDA

Missouri Coalition for Community Behavioral Healthcare
221 Metro Drive, Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:10	Minutes Review	Discussion/Approval
10:10 - 10:25	Pharmacy Program/ Budget Update	Stephen Calloway/Mitch Ruth
10:25 - 10:30	DUR Update	Stephen Calloway

Old Business

10:30 – 10:45	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Stephen Calloway
	<ul style="list-style-type: none">• Short-Acting Single and Combination Opioids Clinical Edit	

New Business

10:45 – 11:15	B. Proposed Actions- New Drug/Product Review (See website and Attached Summary)	Stephen Calloway
---------------	---	------------------

- I. Open Access**
- II. Clinical Edit/Fiscal Edit/Step Therapy**
- III. PDL Products**
- IV. Prior Authorization**
 - Discussion
 - Public Hearing
 - Decision

11:15 – 11:45	C. <u>Clinical Edits</u> <ul style="list-style-type: none">I. Brineura Clinical Edit<ul style="list-style-type: none">• Discussion• Public Hearing• DecisionII. Respiratory Monoclonal Antibodies Clinical Edit<ul style="list-style-type: none">• Discussion• Public Hearing• DecisionIII. Morphine-Milligram-Equivalent Accumulation Edit<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
---------------	---	--

D. Preferred Drug List (PDL)

- I. Actinic Keratosis Agents – Topical**
 - Discussion
 - Public Hearing
 - Decision
- II. Androgenic Agents – Topical**
 - Discussion
 - Public Hearing
 - Decision
- III. Antibiotics - Inhaled**
 - Discussion
 - Public Hearing
 - Decision
- IV. Antifungals (Onychomycosis Agents) – Oral**
 - Discussion
 - Public Hearing
 - Decision
- V. Antifungals – Topical**
 - Discussion
 - Public Hearing
 - Decision
- VI. Antihistamines – Intranasal**
 - Discussion
 - Public Hearing
 - Decision
- VII. Antihistamines – Low-Sedating (2nd Generation)**
 - Discussion
 - Public Hearing
 - Decision
- VIII. Antihistamines/Decongestants – Low-Sedating**
 - Discussion
 - Public Hearing
 - Decision
- IX. Antihistamines – Ophthalmic**
 - Discussion
 - Public Hearing
 - Decision
- X. Antiparasitics – Topical**
 - Discussion
 - Public Hearing
 - Decision

- XI. Antivirals - Topical**
 - Discussion
 - Public Hearing
 - Decision
- XII. Atopic Dermatitis Agents (Topical Immunomodulators)**
 - Discussion
 - Public Hearing
 - Decision
- XIII. Benzoyl Peroxide/Antibiotic Combinations – Topical**
 - Discussion
 - Public Hearing
 - Decision
- XIV. Beta Adrenergic Agents (Long-Acting)**
 - Discussion
 - Public Hearing
 - Decision
- XV. Beta Adrenergic Agents – Nebulized**
 - Discussion
 - Public Hearing
 - Decision
- XVI. Beta Adrenergic Agents (Short-Acting)**
 - Discussion
 - Public Hearing
 - Decision
- XVII. COPD Anticholinergic Agents**
 - Discussion
 - Public Hearing
 - Decision
- XVIII. Corticosteroids – Intranasal**
 - Discussion
 - Public Hearing
 - Decision
- XIX. Corticosteroids – Oral Inhaled**
 - Discussion
 - Public Hearing
 - Decision
- XX. Corticosteroids – Topical**
 - Discussion
 - Public Hearing
 - Decision

- XXI. Cough & Cold Products**
 - Discussion
 - Public Hearing
 - Decision
- XXII. Cough & Cold Opioid Combination Products**
 - Discussion
 - Public Hearing
 - Decision
- XXIII. Epinephrine Self-Injectable Products**
 - Discussion
 - Public Hearing
 - Decision
- XXIV. Fluoroquinolones – Ophthalmic**
 - Discussion
 - Public Hearing
 - Decision
- XXV. Fluoroquinolones – Otic**
 - Discussion
 - Public Hearing
 - Decision
- XXVI. Herpes Antivirals – Oral**
 - Discussion
 - Public Hearing
 - Decision
- XXVII. Leukotriene Modifiers – Oral**
 - Discussion
 - Public Hearing
 - Decision
- XXVIII. Mast Cell Stabilizers – Ophthalmic**
 - Discussion
 - Public Hearing
 - Decision
- XXIX. NSAIDs – Ophthalmic**
 - Discussion
 - Public Hearing
 - Decision
- XXX. Pancreatic Enzymes**
 - Discussion
 - Public Hearing
 - Decision

- XXXI. Prostaglandin Agonists (Glaucoma Agents)**
 - Discussion
 - Public Hearing
 - Decision
- XXXII. Psoriasis Agents – Oral**
 - Discussion
 - Public Hearing
 - Decision
- XXXIII. Psoriasis Agents – Topical**
 - Discussion
 - Public Hearing
 - Decision
- XXXIV. Retinoids – Topical**
 - Discussion
 - Public Hearing
 - Decision
- XXXV. Ulcerative Colitis Agents – Oral**
 - Discussion
 - Public Hearing
 - Decision
- XXXVI. Ulcerative Colitis Agents - Rectal**
 - Discussion
 - Public Hearing
 - Decision

E. Preferred Drug List Classes for June/July

- I. Process Discussion
- II. Therapeutic classes/to be announced at meeting

- | | | |
|-----------|--|--------------|
| 1:30 pm | LUNCH | |
| 1:45-2:00 | Program Utilization Information - Conduent Update | Luke Boehmer |
| 2:00-2:15 | Other Business | |
| | <ul style="list-style-type: none"> ▪ <i>“Top 25” Drugs by Cost/Claims</i> ▪ <i>Clinical Edit Summary Report</i> ▪ <i>Call Center Statistics</i> | |

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: Thursday, June 21, 2018

Department of Natural Resources - Lacharette/Nightingale Rooms
1101 Riverside Drive, Jefferson City, MO